Hosted by ACE Oncology · 🇺🇸 US · EN-US · 50 episodes
Established thought leaders with verified media credentials.
The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.
ACE Oncology hosts ACE OncoCast, a education show with 50 episodes published.
Natalia Carballo, MD Sanitas Hospitals/Atrys Health Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting i
Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 ta
Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targ
Enrique Grande, MD, MSc, PhD Quirónsalud Madrid Madrid, Spain The therapeutic landscape for urothelial cancer (UC) has undergone significant transformation in recent years, with the addition of PD-1/PD-L1 targeting immun
Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immun
Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targetin
Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting
Enrique Grande, MD, MSc, PhD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeti
Episode 2: Case 1: First-line treatment with maintenance immunotherapy for a platinum-eligible patient Case 2: First-line treatment with mono-immunotherapy for a cisplatin-ineligible patient Joachim Chan, BSc, MBBS, MRCP
Episode 1: Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Enrique Grande, MD, MSc, PhD The therapeutic landscape of unresectab
Episode 3: Panel Discussion & Pearls for Practice Aristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhD The increasing availability of treatment options in the first-line (1L) sett
Episode 2: Case 1: Second-line and salvage treatment options after maintenance immunotherapy Case 2: Second-line and salvage treatment options after platinum-based chemotherapy Kate Smith, MBBS, MRCP, MD, PhD The increas
Episode 1: Opening & Keynote Speech: Second-line and salvage treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Philippe Barthélémy, MD, PhD The increasing availabilit
Episode 3: Panel Discussion & Pearls for Practice Fernando Maluf, MD, PhD, Enrique Grande, MD, MSc, PhD and Joachim Chan, BSc, MBBS, MRCP, FRCR, MD The therapeutic landscape of unresectable locally advanced or metastatic
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates
About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunothe
Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist multidiscipl
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch ACE OncoCast, visit https://aceoncocast.buzzsprout.com for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent education coverage.
ACE OncoCast is hosted by ACE Oncology. The show is categorised under education and has published 50 episodes.
ACE OncoCast has published 50 episodes.
ACE OncoCast regularly covers education. It sits in the education category.
ACE OncoCast is accessible for guests with genuine education expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
ACE OncoCast hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of ACE OncoCast average 17 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates ACE OncoCast's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.
